Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya30830Editorial articleПередовая статьяHyperuricemia as a component of cardiorenal syndromeГиперурикемия как компонент кардиоренального синдромаMukhinNikolay AlekseevichМухинНиколай Алексеевич

д-р мед. наук, проф., акад. РАМН, зав. каф. терапии и профболезней МПФ, дир. клиники нефрологии, внутренних и профессиональных болезней им. Е. М. Тареева Университетской клинической больницы № 3 ГОУ ВПО Первый МГМУ им. И. М. Сеченова; ГОУ ВПО Первый МГМУ им. И. М. Сеченова Минздравсоцразвития России

moukhin-nephro@yandex.ruFominViktor ViktorovichФоминВиктор Викторович

д-р мед. наук, проф. каф. терапии и профболезней МПФ, декан фак. довузовского образования Первый МГМУ им. И. М. Сеченова; ГОУ ВПО Первый МГМУ им. И. М. Сеченова Минздравсоцразвития России

fomin_vic@mail.ruLebedevaM VЛебедеваМ В

канд. мед. наук, доц. каф. терапии и профболезней МПФ Первый МГМУ им. И. М. Сеченова; ГОУ ВПО Первый МГМУ им. И. М. Сеченова Минздравсоцразвития России

MukhinN A

I.M. Sechenov First Moscow State Medical University

FominV V

I.M. Sechenov First Moscow State Medical University

LebedevaM V

I.M. Sechenov First Moscow State Medical University

ГОУ ВПО Первый МГМУ им. И. М. Сеченова Минздравсоцразвития РоссииI.M. Sechenov First Moscow State Medical University15062011836NO6 (2011)ТОМ 83, №6 (2011)51310042020Copyright ©; 2011, Consilium MedicumCopyright ©; 2011, ООО "Консилиум Медикум"2011Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/30830

The role of hyperuricemia as a cardiovascular and renal risk factor and approaches to its correction are discussed.

Обсуждается значение гиперурикемии как фактора риска развития сердечно-сосудистых осложнений и хронической болезни почек, а также показания к ее коррекции.

hyperuricemiachronic kidney diseasecardiovascular complicationscardio-renal syndromeгиперурикемияхроническая болезнь почексердечно-сосудистые осложнениякардиоренальный синдромМухин Н. А., Балкаров И. М. Подагрическая почка. В кн.: Тареева И. Е. (ред.). Нефрология: Руководство для врачей. М.: Медицина; 2000. 422-427.Domrongkitchaiporn S., Sritara P., Kitiyakara C. et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J. Am. Soc. Nephrol. 2005; 16: 791-799.Тареев Е. М. Гипертоническая болезнь. М.: Медгиз; 1948.Dolder M. A., Oliver M. F. Myocardial infarction in young men. Study of risk factors in nine countries. Br. Heart J. 1975; 37 (5): 493-503.Culleton B. F., Larson M. G., Kannel W. B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med. 1999; 131 (1): 7-13.Yang Q., Guo C. Y., Cupples L. A. et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism, 2005; 54 (11): 1435-1441.Gordon T., Kannel W. B. Drinking and its relation to smoking, BP, blood lipids, and uric acid. The Framingham study. Arch. Intern. Med. 1983; 143 (7): 1366-1374.Sharpe C. R. A case-control study of alcohol consumption and drinking behaviour in patients with acute gout. Can. Med. Assoc. J. 1984; 131 (6): 563-567.Miao Z., Li C., Chen Y. et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J. Rheumatol. 2008; 35 (9): 1859-1864.Gaffo A. L., Roseman J. M., Jacobs D. R. Jr. et al. Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Ann. Rheum. Dis. 2010 Jun 4. [Epub ahead of print]Choi H. K., Atkinson K., Karlson E. W. et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004; 363 (9417): 1277-1281.Bhole V., de Vera M., Rahman M. M. et al. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthr. and Rheum. 2010; 62 (4): 1069-1076.Reyes A. J. Cardiovascular drugs and serum uric acid. Cardiovasc. Drugs Ther. 2003; 17 (5-6): 397-414.Gurwitz J. H., Kalish S. C., Bohn R. L. et al. Thiazide diuretics and the initiation of anti-gout therapy. J. Clin. Epidemiol. 1997; 50 (8): 953-959.Bomback A. S., Derebail V. K., Shoham D. A. et al. Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int. 2010; 77 (7): 609-616.Borges R. L., Hirota A. H., Quinto B. M. et al. Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. J. Clin. Hypertens. (Greenwich) 2009; 11 (5): 253-259.Choi J. W., Ford E. S., Gao X., Choi H. K. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthr. and Rheum. 2008; 59 (1): 109-116.Choi H. K., Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Br. Med. J. 2008; 336 (7639): 309-312.Hak A. E., Choi H. K. Menopause, postmenopausal hormone use and serum uric acid levels in US Women the Third National Health and Nutrition Examination Survey. Arthr. and Res. Ther. 2008; 10 (5): R116.Indraratna P. L., Williams K. M., Graham G. G., Day R. O. Hyperuricemia, cardiovascular disease, and the metabolic syndrome. J. Rheumatol. 2009; 36 (12): 2842-2843.Carnethon M. R., Fortmann S. P., Palaniappan L. et al. Risk factors for progression to incident hyperinsulinemia: the Atherosclrosis Risk in the Communities Study, 1987-1998. Am. J. Epidemiol. 2003; 158: 1058-1067.Choi H. K., Ford E. S. Prevalence of metabolic syndrome in individuals with hyperuricemia. Am. J. Med. 2007; 120: 442-447.Донсков А. С., Балкаров И. М., Голубь Г. В. и др. Клиническое значение индекса массы тела и индекса талия/бедро у пациентов с артериальной гипертонией: связь с уровнем мочевой кислоты в крови. Клин. мед. 2002; 80 (1): 31-34.Villegas R., Xiang Y. B., Cai Q. et al. Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men. Metab. Syndr. Relat. Disord. 2010; 8 (3): 263-270.Sui X., Church T. S., Meriwether R. A. et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism 2008; 57 (6): 845-852.Puig J. G., Martinez M. A., Mora M. et al. Serum urate, metabolic syndrome, and cardiovascular risk factors. A population-based study. Nucleosid. Nucleotid. Nucl. Acids 2008; 27 (6): 620-623.Li N. F., Wang H. M., Yang J. et al. Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population. Appl. Physiol. Nutr. Metab. 2009; 34 (6): 1032-1039.Choi H. K., Ford E. S. Haemoglobin Alc, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels - the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford) 2008; 47 (5): 713-717.Rocic B., Vucic-Lovrencic M., Poje N. et al. Uric acid may inhibit glucose induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells. Bioorg. Med. Chem. Lett. 2005; 15 (4): 1181-1184.Chien K. L., Chen M. F., Hsu H. C. et al. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin. Chem. 2008; 54 (2): 310-316.Rizos C. V., Liberopoulos E. N., Mikhailidis D. P., Elisaf M. S. Pleiotropic effects of thiazolidinediones. Expert. Opin. Pharmacother. 2008; 9 (7): 1087-1108.Vitart V., Rudan I, Hayward C. et al. SLC2A9 is a newly identified urate transopter influencing serum urate concentrations, urate excretion and gout. Nat. Genet. 2008; 40: 437-442.Doring A., Gieger C., Mehta D. et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat. Genet. 2008; 40: 430-436.Graessler J., Graessler A., Unger S. et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthr. and Rheum. 2006; 54 (1): 292-300.Li C., Han L., Levin A. M. et al. Multiple single nucleotide polymorphisms in the human urate transporter 1 (hURATl) gene are associated with hyperuricaemia in Han Chinese. J. Med. Genet. 2010; 47 (3): 204-210.Jang W. C., Nam Y. H., Park S. M. et al. T6092C polymorphism of SLC22A12 gene is associated with serum uric acid concentrations in Korean male subjects. Clin. Chim. Acta 2008; 398 (1-2): 140-144.Chaves F. J., Corella D., Blesa D. et al. Xanthine oxidoreductase polymorphisms: influence in blood pressure and oxidative stress levels. Pharmacogenet. Genom. 2007; 17: 589-596.Watanabe S., Kang D. H., Feng L. et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40 (3): 355-360.Feig D. I., Kang D.-H., Johnson R. J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008; 359 (17): 1811-1821.Sundstrom J., Sullivan L., D'Astino R. B. et al. Relations of serum uric acid to longitudinal blood pressure traching and hypertension incidence. Hypertension 2005; 45: 28-33.Krishnan E., Kwoch C. K., Schumaher H. R., Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 298-303.Lu Z. S., Lu Z. H., Lu H. et al. Association between hyperuricemia and hypertension in a Chinese population at a high risk of hypertension. Blood Press. 2009; 18 (5): 268-272.Ouppatham S., Bancha S., Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. J. Postgrad. Med. 2008; 54 (4): 259-262.Lee I. E., Kim Y. G., Choi Y. H. et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006; 47: 962-967.Alper A. B. Jr., Chen W., Yau L. et al. Childhood uric acid predicts adult blood pressure. The Bogalusa Heart Study. Hypertension 2005; 45: 34-38.Jones D. P., Richey P. A., Alpert B. S., Li R. Serum uric acid and ambulatory blood pressure in children with primary hypertension. Pediatr. Res. 2008; 64 (5): 556-561.Мухин Н. А., Балкаров И. М., Шоничев Д. Г., Лебедева М. В. Формирование артериальной гипертонии при уратном тубулоинтерстициальном нефрите. Тер. арx. 1999; 71 (6): 23-27.Viazzi F., Leoncini G., Ratto E. et al. Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am. J. Hypertens. 2007; 20 (12): 1276-1282.Domrongkitchaiporn S., Sritara P., Kitiyakara C. et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J. Am. Soc. Nephrol. 2005; 16: 791-799.Iseki K., Oshiro S., Tozawa M. et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens. Res. 2001; 24: 691-697.Shan Y., Zhang Q., Liu Z. et al. Prevalence and risk factors associated with chronic kidney disease in adults over 40 years: a population study from Central China. Nephrology (Carlton) 2010; 15 (3): 354-361.Satirapoj B., Supasyndh O., Chaiprasert A. et al. Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population. Nephrology (Carlton) 2010; 15 (2): 253-258.Chang H. Y., Tung C. W., Lee P. H. et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am. J. Med. Sci. 2010; 339 (6): 509-515.Ingsathit A., Thakkinstian A., Chaiprasert A. et al.; Thai-SEEK Group. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol. Dial. Transplant. 2010; 25 (5): 1567-1575.Tsai J. C., Chen S. C., Hwang S. J. et al. Prevalence and risk factors for CKD in spouses and relatives of hemodialysis patients. Am. J. Kidney Dis. 2010; 55 (5): 856-866.Mazzali M., Hughes J., Kim Y. G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38 (5): 1101-1106.Kang D. H., Nakagawa T., Feng L. et al. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 2002; 13 (12): 2888-2897.Sänchez-Lozada L. G., Tapia E., Santamaria J. et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005; 67 (1): 237-247.Kanellis J., Kang D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 2005; 25 (1): 39-42.Щербак А. В., Балкаров И. М., Козловская Л. В. и др. Фибринолитическая активность мочи как показатель поражения почек при нарушении обмена мочевой кислоты. Tep. apx. 2001; 73 (6): 34-37.Albertoni G., Maquigussa E., Pessoa E. et al. Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells. Exp. Biol. Med. (Maywood) 2010; 235 (7): 825-832.Kosugi T., Nakayama T., Heinig M. et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am. J. Physiol. Renal Physiol. 2009; 297 (2): F481-F488.Haririan A., Nogueira J. M., Zandi-Nejad K. et al. The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation 2010; 89 (5): 573-579.Siu Y. P., Leung K. T., Tong M. K., Kwan T. H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 2006; 47 (1): 51-59.Navaneethan S. D., Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol. Dial. Transplant. 2009; 24 (4): 1260- 1266.Suliman M. E., Johnson R. J., Garcia-López E. et al. J-shaped mortality relationship for uric acid in CKD. Am. J. Kidney Dis. 2006; 48 (5): 761-771.Wen C. P., David Cheng T. Y., Chan H. T. et al. Is high serum uric acid a risk marker or a target for treatment? examination of its independent effect in a large cohort with low cardiovascular risk. Am. J. Kidney Dis. 2010 Jun 2. [Epub ahead of print]Fang J., Alderman M. H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. J. A. M. A. 2000; 283 (18): 2404-2410.Krishnan E., Svendsen K., Neaton J. D. et al.; MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch. Intern. Med. 2008; 168 (10): 1104-1110.Baker J. F., Schumacher H. R., Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 2007; 58 (4): 450-457.Langlois M., De Bacquer D., Duprez D. et al. Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis 2003; 168 (1): 163-168.Chen J. H., Chuang S. Y., Chen H. J. et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthr. and Rheum. 2009; 61 (2): 225-232.Kim S. Y., Guevara J. P., Kim K. M. et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthr. and Rheum. 2009; 61 (7): 885-892.Kim S. Y., Guevara J. P., Kim K. M. et al. Hyperuricemia and coronary heart disease: a systematic review and meta analysis. Arthr. Care Res. (Hoboken) 2010; 62 (2): 170-180.Okura T., Higaki J., Kurata M. et al.; Japanese Coronary Artery Disease Study Investigators. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ. J. 2009; 73 (5): 885-891.Choi H. K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116 (8): 894-900.Dunkelgrun M., Welten G. M., Goei D. et al. Association between serum uric acid and perioperative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery. Am. J. Cardiol. 2008; 102 (7): 797-801.Iwashima Y., Horio T., Kamide K. et al. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47 (2): 195-202.Kuo C. F., Yu K. H., Luo S. F. et al. Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. Rheumatology (Oxford) 2010; 49 (6): 1189-1196.Tavil Y., Kaya M. G., Oktar S. O. et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis 2008; 197 (1): 159-163.Kawamoto R., Tomita H., Oka Y. et al. Association between uric acid and carotid atherosclerosis in elderly persons. Intern. Med. 2005; 44 (8): 787-793.Neogi T., Ellison R. C., Hunt S. et al. Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute,Family Heart Study. J. Rheumatol. 2009; 36 (2): 378-384.Pacifico L., Cantisani V., Anania C. et al. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur. J. Endocrinol. 2009; 160 (1): 45-52.Li Y., Xu C., Yu C. et al. Association of serum uric acid level with nonalcoholic fatty liver disease: a cross-sectional study. J. Hepatol. 2009; 50 (5): 1029-1034.Yamamoto Y., Matsubara K., Igawa G. et al. Status of uric acid management in hypertensive subjects. Hypertens. Res. 2007; 30 (6): 549-554.Goicoechea M., Vinuesa S. G., Verdalles U. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 2010 Jun 10. [Epub ahead of print]Kanbay M., Ozkara A., Selcoki Y. et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int. Urol. Nephrol. 2007; 39 (4): 1227-1233.Hoieggen A., Alderman M. H., Kjeldsen S. E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65: 1041-1049.Мухин Н. А., Балкаров И. М., Моисеев С. В. и др. Урикозурическое действие лозартана. Клин. фармакол. и тep. 2003; 5: 59-63.Athyros V. G., Elisaf M., Papageorgiou A. A. et al.; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am. J. Kidney Dis. 2004; 43 (4): 589-599.Ogata N., Fujimori S., Oka Y., Kaneko K. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosid. Nucleotid. Nucl. Acids 2010; 29 (4-6): 321-324.Berbari A. The role of uric acid in hypertension, cardiovascular events and chronic kidney disease. ESH Scient. Newslett. 2010; 11: N49.